MYO1B

Across TCGA pan-cancer cohorts, MYO1B mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated MYO1B data layer compared with 28 for mass-spec protein and 8 for mutation status.

The strongest signal is observed in glioblastoma multiforme (GBM), where higher MYO1B mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated MYO1B expression acts as an unfavorable survival marker, although some lineages such as GBM show a favorable association.

GBM, PDAC, and LUAD are the cancer types where MYO1B mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
GBM	DFS	Tertile	All	0.560	0.242	.007	13	view →
PDAC	DFS	Tertile	IV	0.182	0.515	.024	5	view →
LUAD	DFS	Quartile	II,III,IV	0.732	0.911	.039	3	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

MYO1B–GBM (DFS)

Open the GBM breakdown →